[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,554
  • Shares Outstanding, K 21,411
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,450 K
  • EBIT $ -6 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.21
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.08 on 05/13/26
  • Next Earnings Date 08/11/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 1
  • High Estimate $-0.09
  • Low Estimate $-0.09
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2695 +15.03%
on 07/23/26
0.4100 -24.39%
on 07/06/26
-0.0601 (-16.24%)
since 07/02/26
3-Month
0.2695 +15.03%
on 07/23/26
0.5900 -47.46%
on 05/04/26
-0.2570 (-45.33%)
since 05/01/26
52-Week
0.2695 +15.03%
on 07/23/26
2.1100 -85.31%
on 09/08/25
-0.6094 (-66.28%)
since 08/01/25

Most Recent Stories

More News
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC

KAPA : 0.3100 (+1.27%)
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever

Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.Founded...

KAPA : 0.3100 (+1.27%)
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

Zero Grade 3+ Toxicities associated with ENV-105 in 13 Patients; ENV-105 (Carotuximab) Demonstrates Clean Safety Profile in Combination with Osimertinib (AstraZeneca's Tagrisso®) — Advancing Kairos's...

KAPA : 0.3100 (+1.27%)
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest...

KAPA : 0.3100 (+1.27%)
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award

Company selected for the Leaders in Drug Resistance Development award

KAPA : 0.3100 (+1.27%)
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset...

KAPA : 0.3100 (+1.27%)
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

Kairos Pharma, Ltd. (NYSE American: KAPA) , a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually...

KAPA : 0.3100 (+1.27%)
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Company selected as an Emerald honoree for Innovator of Biotech Solutions

KAPA : 0.3100 (+1.27%)
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE American: KAPA)...

KAPA : 0.3100 (+1.27%)
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE American: KAPA) resulting from allegations...

KAPA : 0.3100 (+1.27%)

Business Summary

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based...

See More

Key Turning Points

3rd Resistance Point 0.3465
2nd Resistance Point 0.3333
1st Resistance Point 0.3216
Last Price 0.3100
1st Support Level 0.2967
2nd Support Level 0.2835
3rd Support Level 0.2718

See More

52-Week High 2.1100
Fibonacci 61.8% 1.4069
Fibonacci 50% 1.1897
Fibonacci 38.2% 0.9726
Last Price 0.3100
52-Week Low 0.2695

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.